Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
about
Health-related quality of life in patients with primary immunodeficiency diseaseSelf-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptanceExperience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141)A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin.Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatmentCommon variable immunodeficiency: etiological and treatment issues.Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.Quality of life in children with primary antibody deficiency.Primary immune deficiencies - principles of care.Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapySubcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiencyRecombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model.Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.Use of subcutaneous immunoglobulin in primary immune deficiencies.The use of i.v. IG therapy in dermatology.Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.Subcutaneous immunoglobulin: opportunities and outlook.Immunotherapy of multifocal motor neuropathy.Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease.Why I use subcutaneous immunoglobulin (SCIG).Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
P2860
Q26784167-39D87F77-3800-4D87-8AF8-A278756FECB4Q28079761-016D578F-DB38-4FC3-B72A-24DE5F7A2119Q28546873-EBB135E2-E51F-4DD0-91D0-E534852F0FAEQ33399594-70715019-31E9-4645-AE15-534A0513901BQ33417506-7220DF73-B685-4DC9-BB98-E48803D07533Q33583520-EBC4AA16-404E-4F77-9043-40F88912E113Q33621805-E10B7C28-9FA2-4750-A6BE-0479A0F914E5Q33635013-13392940-AD6E-421F-AFF9-5CD7791BEC72Q33692418-069B99EE-E522-432D-9E50-778D1E09042BQ33695997-376B96BC-1864-418B-B0FA-315A12D48A87Q33878939-A948AB7F-F07A-4E21-8673-CA642834222BQ34196126-4528ABE1-89DC-4EF9-9579-A331ACE0F35AQ34700023-DDE047F1-89C9-4170-8BAC-3657CB9A2818Q34753641-09D67A8D-70A8-4538-B434-D569AB661327Q35103593-37EE25C6-426B-4FED-8D02-869122F42835Q35566525-CC6E6633-8020-40B3-B308-A853CC3946CDQ35580799-7D4EFED0-8808-4366-BEDF-8E3410BE1D1AQ35959163-D1337D60-5E20-411D-858F-C070BACF2333Q36149327-4C1D176F-4D33-4D60-BD7E-E5485B40B5AEQ36196688-84B06839-8F7C-4880-858C-FB95124F205EQ36687522-05522B0D-3526-4AEF-8CCF-F1D114200DEAQ36791300-52AC1FF5-E80A-4131-A154-9F9D40AC4028Q36986054-1B756689-3F06-4439-AE29-BA58857AB6BAQ37031111-CC3F6C1D-97F3-4F41-88F7-B21316AFA177Q37083973-609CEE0E-0D02-4A5D-B965-53446C970739Q37125900-A23608E6-E5A3-489B-95EF-A1E1C4850A60Q37626132-02495BD6-712B-4BE3-B810-D0511980BB6EQ37836898-46EAE6EE-3E56-47FE-AF04-5F320FAF8993Q37890936-CB0E675B-FAED-47F3-8F83-0019CBA46EDBQ37929510-62B49557-3C13-4C9F-943E-A02DCA3769E4Q38021422-F55B2BB1-FCF5-48BE-871C-526892C147AFQ38029244-C3456931-5778-4278-BDFF-FAB2E5D610F3Q38065205-9841E9C3-3DEA-4CC4-85A4-9F015570936CQ38069527-2F55D778-21C7-49CC-A02A-EED1B2C18472Q38075120-4FB90100-2D24-4A9A-9C01-69B4A7209F67Q38100810-85BD20E9-6162-4A16-A971-A41234516478Q38122120-C9F53FF6-2BEF-4767-9864-7BF79D49E463Q38217591-2F12C1D6-4BCE-4938-8C70-0E477B9200DDQ38266635-1F9361B9-AF8F-4DD0-BCD4-25934330A423Q38390889-FE0FEE8B-76F3-460E-8FFC-EAB4D4DD2402
P2860
Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Children and adults with prima ...... us IgG self-infusions at home.
@en
Children and adults with prima ...... us IgG self-infusions at home.
@nl
type
label
Children and adults with prima ...... us IgG self-infusions at home.
@en
Children and adults with prima ...... us IgG self-infusions at home.
@nl
prefLabel
Children and adults with prima ...... us IgG self-infusions at home.
@en
Children and adults with prima ...... us IgG self-infusions at home.
@nl
P2093
P1476
Children and adults with prima ...... us IgG self-infusions at home.
@en
P2093
Andreas Böck
Ann Gardulf
Beatriz T Costa-Carvalho
Carl Granert
Dolores Hernández
Ilka Schulze
Michael Borte
Nuria Matamoros
P304
P356
10.1016/J.JACI.2004.06.053
P407
P577
2004-10-01T00:00:00Z